ClinicalTrials.gg
TerminatedNCT04039347BOSTON-3Updated Apr 7, 2026

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

A Phase 3 interventional study of Liposomal Cyclosporine A 5 mg and Liposomal Cyclosporine A 10 mg in Bronchiolitis Obliterans, Obliterative Bronchiolitis and Bronchiolitis Obliterans Syndrome, sponsored by Zambon SpA. Terminated at 37 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Primary conditionBronchiolitis Obliterans SyndromeRegistry: Bronchiolitis ObliteransReclassifiedWhy we changed it
Registry
Bronchiolitis Obliterans — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchiolitis Obliterans Syndrome
Why
  1. The study's listed conditions name Bronchiolitis Obliterans Syndrome, a narrower term within Bronchiolitis Obliterans.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Zambon SpA · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated for business reasons. The earlier study end is not related to any safety concerns or data issues identified at any site or within the overall study data collected to date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Enrollment
55th of 260
164 · median 45
Started
2020
with 12 others
Phase 3
30 of 300
4 open now
Registered
204th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 55th largest by enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2020, is one of 30 in phase 3, and was the 204th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.

Read the detailed description

This is a Phase III, multicenter, open-label, extension clinical trial of L-CsA for the treatment of BOS.

Enrollment will be limited to patients who have completed 48 weeks participation in either the BT-L-CsA-301-SLT (BOSTON-1) or BT-L-CsA-302-DLT (BOSTON-2) trial. All patients in this clinical trial will receive L-CsA in addition to SoC, regardless of the randomization arm in prior trials.

IMP will be administered by BID inhalation (morning/evening) using the L-CsA eFlow. Patients who did not receive L-CsA in BOSTON-1 or BOSTON-2 must remain in the clinic for at least 4 hours for observation after the first inhalation. At all subsequent visits, one dose administered via inhalation will be monitored by the clinical trial center personnel. In case patients receiving L-CsA undergo the last visit for BOSTON-1 or BOSTON-2 (Visit 9) on the same day as for Visit 1 for BOSTON-3, they will take the first dose for Boston 3 in the evening of this day. This first dose will not be supervised by the site staff. Nebulization time per inhalation dose is approximately 6-10 minutes for the 5 mg dose and 9-13 minutes for the 10 mg dose. Inhalations will be performed BID approximately 12 hours apart through a mouthpiece by slow and deep respiration using the L-CsA eFlow. A high efficiency particulate air filter is used to prevent environmental contamination during exhalation.

03

Conditions studied

  • Bronchiolitis Obliterans
  • Obliterative Bronchiolitis
  • Bronchiolitis Obliterans Syndrome

Browse trials for

Keywords

  • single and double transplant
04

In context

Bronchiolitis Obliterans Syndrome Reclassified

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

This study's enrollment of 164 is above the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.

Browse Bronchiolitis Obliterans Syndrome studies →

Lead sponsor

Zambon SpA is the lead sponsor of 23 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Compared within Bronchiolitis Obliterans Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bronchiolitis Obliterans. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have completed all visits through the End of Treatment Visit in either BOSTON-1 or BOSTON-2, did not withdraw , and did not prematurely terminate study drug administration.
  2. Patients should be on a three-drug maintenance regimen of agents including tacrolimus or another CNI, a second agent such as but not limited to MMF or azathioprine, and a systemic such as prednisone.
  3. Patients capable of understanding the purposes and risks of the clinical trial, who have given written informed consent and agree to comply with the clinical trial requirements/visit schedules, and who are capable of aerosol inhalation.
  4. Women of must have a negative serum pregnancy test within 7 days prior to Visit 1 and must agree to use one of the methods of listed in Appendix II through their End of Study Visit.

Exclusion criteria

Exclusion Criteria:

  1. Known to L-CsA or to cyclosporine A.
  2. Patients who experienced an AE related to study drug that led to permanent study drug discontinuation in BOSTON-1 or BOSTON-2.
  3. Patients with new onset of while participating in BOSTON-1 or BOSTON-2, including post-transplant lymphoproliferative disorder, with the exception of treated, localized basal and squamous cell carcinomas.
  4. Pregnant women or women who are unwilling to use appropriate to avoid pregnancy through their End of Study Visit.
  5. Women who are currently breastfeeding.
  6. Receipt of an drug, other than L-CsA, as part of a clinical trial within 4 weeks prior to Visit 1. This is defined as any treatment that is implemented under an Investigational New Drug (IND) or compassionate use.
  7. Patients who are currently participating in an interventional clinical trial, other than BOSTON-1 or BOSTON-2.
  8. Psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures.
  9. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    L-CsA 5 mg plus Standard of Care

    L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant

    Drug: Liposomal Cyclosporine A 5 mg

  • Experimental
    L-CsA 10 mg plus Standard of Care

    L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant

    Drug: Liposomal Cyclosporine A 10 mg

Interventions

  • delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

    Also known as: L-CsA

  • delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

    Also known as: L-CsA

07

What researchers measure

Primary outcomes

  1. Mean change in FEV1 from Baseline to Week 24

    FEV1 is the Forced Expiratory Volume in One Second

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Mean change in FEV1 from Baseline to Week 48

    FEV1 is the Forced Expiratory Volume in One Second

    Time frame: Baseline to Week 48

  2. Mean change in FEV1 from Baseline to End of Study

    FEV1 is the Forced Expiratory Volume in One Second

    Time frame: Baseline to end of study, approximately 2 years

  3. Mean change in FEV1/FVC from Baseline to Week 24

    FEV1/FVC is the ratio between Forced Expiratory Volume in One Second and Forced Vital Capacity.

    Time frame: Baseline to Week 24

  4. Mean change in FEV1/FVC from Baseline to Week 48

    FEV1/FVC is the ratio between Forced Expiratory Volume in One Second and Forced Vital Capacity.

    Time frame: Baseline to Week 48

  5. Time to Progression of BOS

    The Progression of BOS is defined as the earliest of: * Absolute decrease from baseline in FEV1 \>/= 10% or \>/= 200 mL and absolute decrease in FEV1/FVC of \> 5%, OR * Change in BOS severity (according to criteria in Verleden 2019), OR * Re-transplantation, OR * Death from respiratory failure

    Time frame: Baseline to End of Study, approximately 2 years

Other outcomes

  1. Adverse events

    An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.

    Time frame: Baseline through end of study, approximately 2 years

  2. Acute tolerability of L-CsA as measured by change in FEV1 at 1 hour and 4 hours after first inhalation of L-CsA

    Parameters reflecting acute tolerability of IMP are: * spirometry, before and 1 hour and 4 hours after inhalation of L-CsA at initial dosing. * cough, or * dyspnea.

    Time frame: First treatment with L-CsA

  3. Acute tolerability of L-CsA as measured by number of patients with treatment-related adverse events

    Acute tolerability of L-CsA is measured by number of patients with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Baseline through end of treatment, approximately 2 years

  4. Number of patients with treatment-related changes in hematology or serum chemistry parameters

    Number of patients with treatment-related changes in hematology or serum chemistry parameters assessed by CTCAE v5.0

    Time frame: Baseline through end of study participation, approximately 2 years

08

Study locations

37 sites
  • Banner - University Medical Center
    Phoenix, Arizona 85006, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • UCSF
    San Francisco, California 94143, United States
  • UCSF Center for Advanced Lung Disease
    Stanford, California 94305, United States
  • University of Florida Dept of Pulmonary Medicine
    Gainesville, Florida 32610, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • UK Albert B. Chandler Hospital
    Lexington, Kentucky 40508, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University Hospital
    Baltimore, Maryland 21287, United States
  • Barnes-Jewish Hospital
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OSU Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Waehringer Guertel
    Vienna, Austria
  • Hôpital Erasme
    Brussels, 1070, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • Hopital Marie Lannelongue
    Le Plessis-Robinson, 92350, France
  • CHU Hopital Nord
    Marseille, France
  • Hopitaux Universitaires de Strasbourg
    Strasbourg, France
  • Hannover Medical School
    Hanover, Germany
  • LMU Klinikum Groshadern
    Munich, Germany
  • Rabin Medical Center
    Petah Tikva, Israel
  • Complexo Hospitalario de A Coruna
    A Coruña, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario Puerta de Hierro - Unidad de Trasplante Pulmonar
    Madrid, 28222, Spain
  • Hospital Marques de Valdecilla
    Santander, Spain
  • Unidad de Trasplante Pulmonar del Hospital La Fe
    Valencia, 46026, Spain
  • Royal Papworth Hospital NHS Foundation Trust
    Cambridge, CB23 3RE, United Kingdom
  • University of Manchester
    Manchester, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Feb 2026, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2019
First posted
Jul 31, 2019
StartActual
Mar 12, 2020
Primary completionActual
Feb 25, 2026
CompletionActual
Feb 25, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04039347
Lead sponsor
Zambon SpA
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Mar 12, 2020
Primary completion
Feb 25, 2026
Completion
Feb 25, 2026
Last update
Apr 7, 2026

Study contacts

Paola R Castellani, MD
study director · Zambon SpA, Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion